

OA mailed 5/20/02

### DETAILED ACTION

Applicant's election without traverse of Group VI, claims 19-20 in Paper No. 8 is acknowledged. Claims 1-18 and 20-53 are cancelled, claim 12 is amended and claims 54-62 are new.

The requirement is still deemed proper and is therefore made FINAL. As a result, claims 19 and 54-62 are pending and under examination.

#### *Information Disclosure Statement*

The information disclosure statement in paper numbers 4 and 7 have been considered. A signed copy is attached hereto.

#### *Drawings*

The drawings have been considered and are not accepted (see attached form PTO 948).

#### *Specification*

1. The disclosure is objected to because of the following informalities: the specification (p. 2-3 and 10) makes reference to an ATCC Accession Number that is not provided. Applicant is advised to review the entire specification for similar errors. Correction is required.

2. The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.

3. The use of the trademark Taqman has been noted in this application (p. 13-14 and 119). It should be capitalized wherever it appears and be accompanied by the generic terminology.

Although the use of trademarks is permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as trademarks.

4. The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code (p. 14 and 17. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

5. This application filed under former 37 CFR 1.62 lacks the necessary reference to the

Please replace the paragraph beginning at page 8, line 27 with the following rewritten paragraph:

-- *Figure 6* is a bar graph depicting the expression of 14094 RNA in a panel of cell lines, detected using [TaqMan] TAQMAM® analysis. Elevated expression of 14094 RNA was detected in DLD-1 and SW 620 cells lines. Both DLD-1 and SW620 are cell lines derived from colorectal carcinomas. SW620 is a lymph node metastasis of a colorectal carcinoma. --

Please replace the paragraph beginning at page 10, line 22 with the following rewritten paragraph:

-- For general information regarding PFAM identifiers, PS prefix and PF prefix domain identification numbers, refer to Sonnhammer et al. (1997) Protein 28:405-420[ and <http://www.psc.edu/general/software/packages/pfam/pfam.html>]. --

Please replace the paragraph beginning at page 10, line 25 with the following rewritten paragraph:

-- A plasmid containing the nucleotide sequence encoding human 14094 (clone "Fbh14094FL") was deposited with American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, on \_\_\_\_\_ and assigned Accession Number \_\_\_\_\_. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

*Fbh14094*

Table 1: Summary of Sequence Information for 14094

Gene	cDNA	ORF	Polypeptide	[Figure]	[ATCC Accession #]
14094	SEQ ID NO:1,	SEQ ID NO:3	SEQ ID NO:2		
14094	SEQ ID NO:11	SEQ ID NO:13	SEQ ID NO: 12		

*BY*  
TAQMAN® analysis. 14094 RNA expression in normal (solid bars) and malignant ("diseased"; hatched bars) tissues from the breast, colon, liver and lung is shown. Elevated expression of 14094 RNA was detected in malignant tissues relative to normal tissues. --

Please replace the paragraph beginning at page 8, line 23 with the following rewritten paragraph:

*B5*  
--] *Figure 5* is a bar graph depicting the expression of 14094 RNA in a panel of normal and tumor human ovarian samples, detected using TAQMAN® analysis. Elevated expression of 14094 RNA was detected in malignant ovarian tissues relative to normal tissues. --

Please replace the paragraph beginning at page 8, line 27 with the following rewritten paragraph:

*B6*  
--] *Figure 6* is a bar graph depicting the expression of 14094 RNA in a panel of cell lines, detected using TAQMAN® analysis. Elevated expression of 14094 RNA was detected in DLD-1 and SW 620 cells lines. Both DLD-1 and SW620 are cell lines derived from colorectal carcinomas. SW620 is a lymph node metastasis of a colorectal carcinoma. --

Please replace the paragraph beginning at page 10, line 22 with the following rewritten paragraph:

*B7*  
--] For general information regarding PFAM identifiers, PS prefix and PF prefix domain identification numbers, refer to Sonnhammer et al. (1997) *Protein* 28:405-420. --

Please delete the paragraph beginning at page 10, line 25 and amend Table 1 as follows:

*BY*  
Table 1: Summary of Sequence Information for 14094

Gene	cDNA	ORF	Polypeptide
14094	SEQ ID NO:1,	SEQ ID NO:3	SEQ ID NO:2
14094	SEQ ID NO:11	SEQ ID NO:13	SEQ ID NO: 12

two predicted non-transmembrane regions located at about amino acids 1 to about 47 (N-terminal non-transmembrane region), and from about amino acids 70 to about 453;

5 a predicted N-glycosylation site (PS00001) located from about amino acids 221 to about 224 of SEQ ID NO:2;

a predicted glycosaminoglycan attachment site (PS00002) located from about amino acids 341 to 344 of SEQ ID NO:2;

six predicted protein kinase C phosphorylation sites (PS00005) located at about amino acids 14 to about 16, from about amino acids 74 to about 76, from about amino acids

10 82 to about 84, from about amino acids 124 to about 126, from about amino acids 214 to about 216, and from about amino acids 365 to about 367 of SEQ ID NO:2;

four predicted casein kinase II phosphorylation sites (PS00006) located at about amino acids 159 to about 162, from about amino acids 276 to 279, from about amino acids 315 to about 318, and from about amino acids 438 to about 441 of SEQ ID NO:2;

15 a predicted tyrosine kinase phosphorylation site (PS00007) located at about amino acids 99 to about 105 of SEQ ID NO:2; and

seven predicted N-myristylation sites (PS00008) located at about amino acids 94 to about 99, from about amino acids 111 to about 116, from about amino acids 193 to about 198, from about amino acids 219 to about 224, from about amino acids 302 to about 307,

20 from about amino acids 391 to about 396, and from about amino acids 421 to about 426 of SEQ ID NO:2.

*277*  
*For general information regarding PFAM identifiers, PS prefix and PF prefix domain identification numbers, refer to Sonnhammer et al. (1997) Protein 28:405-420 and <http://www.psc.edu/general/software/packages/pfam/pfam.html>.*

*25*  
*A plasmid containing the nucleotide sequence encoding human 14094 (clone "Fbh14094FL") was deposited with American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, on \_\_\_\_\_ and assigned Accession Number \_\_\_\_\_. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.*

*My 3-a-0b  
Delete  
Amendm't  
30  
Filed on 3/23/93  
B78*  
 Table 1: Summary of Sequence Information for 14094